Safety-lens research digest
Ipamorelin is the most selective growth hormone secretagogue ever characterized — here is what its safety and tolerability record actually shows.
A clinical-but-plain reading of the published studies: what the molecule does, where the human evidence stops, and what people report, with every quantitative claim cited.
Start here
Ipamorelin is a small lab-made peptide — a chain of just five amino acids — that tells the pituitary gland (a pea-sized gland under the brain) to release a pulse of growth hormone. What makes it stand out is how clean that signal is: in animal studies it raised growth hormone strongly while barely touching the stress hormone cortisol or the hormone prolactin [1]. That selectivity is its whole reputation.
The honest catch is that the human evidence is thin. The one published human trial — for slow bowel recovery after surgery — did not work [3]. No health authority has ever approved ipamorelin for anything. So this site reads the research with a safety eye first: what was measured, in which animal or person, and at what dose, plus what users report and where the unknowns sit. We sell nothing and give no medical advice. What people describe — the upsides and the downsides — is on the effects page.
What the studies actually measured
Ipamorelin (sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2) is a synthetic pentapeptide — a peptide built from five amino-acid building blocks — that activates the ghrelin receptor, formally GHS-R1a (the docking site on cells that the natural "hunger hormone" ghrelin uses) [1]. When it docks, pituitary cells called somatotrophs release a short burst of growth hormone (GH).
Its defining result comes from the 1998 founding study by Raun and colleagues. In rat pituitary cells, anaesthetised rats, and conscious pigs, ipamorelin released GH about as potently as the older peptide GHRP-6 (pig half-maximal dose, the ED50, of 2.3 nmol/kg versus 3.9 nmol/kg for GHRP-6) — yet it did not push ACTH or cortisol above baseline even at doses more than 200 times its GH ED50 [1]. That is the cleanest selectivity profile of any GH secretagogue characterized.
The human picture is much smaller. A 1999 pharmacokinetic study in eight healthy men per dose found dose-proportional kinetics and a terminal half-life of roughly two hours, with the GH pulse peaking about 40 minutes after dosing [2]. A 2024 ferret study — the most recent in-vivo work — found that ipamorelin (1–3 mg/kg) cut chemotherapy-driven weight loss by about 24%, but had no anti-nausea effect [5].
Where the human evidence stops
Ipamorelin has been studied in humans for exactly one indication, and the result was negative. The only published Phase 2 randomized trial (NCT00672074) gave 0.03 mg/kg intravenously twice daily for up to seven days to 114 adults recovering from bowel-resection surgery. It missed its primary endpoint: median time to first tolerated meal was 25.3 hours with ipamorelin versus 32.6 hours with placebo, a difference that did not reach statistical significance (p = 0.15) [3]. No ipamorelin-specific safety signal appeared in that short window, but no efficacy did either.
There are no completed Phase 3 trials and no approved indication anywhere. Recent expert reviews place ipamorelin firmly in the "investigational, promising mechanism, unproven in people" bucket and stress the absence of rigorous human outcome data [16] [18]. Reading it honestly means holding the strong animal mechanism and the empty human-outcome column in view at the same time.
The selectivity story — and its limits
Most of ipamorelin's appeal traces back to one number: cortisol that barely moves. Older GH-releasing peptides such as GHRP-6 and GHRP-2 also raise GH, but they nudge ACTH, cortisol, and prolactin along with it. Ipamorelin's founding characterization showed it leaving those channels essentially flat even far above its GH-active dose [1]. That is a genuine, mechanism-grounded advantage over less selective peptides.
Selectivity is not the same as safety, though. "Doesn't raise cortisol" says nothing about long-term cardiovascular effects, glucose handling, or what years of repeated GH pulses might do — none of which has been studied in humans. A 28-day study of a different ghrelin-receptor agonist found dose-dependent heart-muscle damage in rats [6], a class-level signal that keeps any honest ipamorelin summary cautious about chronic use. The full picture — reported benefits, reported side effects, and cited cautions — is laid out on the Ipamorelin effects page, and every figure traces back to a study in the Ipamorelin references.